Eszter Lazar-Molnar, PhD, D(ABMLI)

Languages

  • English
  • Hungarian

Academic Information

  • Departments: Pathology - Assistant Professor (Clinical)
  • Divisions: Clinical Pathology

Board Certification

  • American Board of Histocompatibility & Immunogenetics
  • American Board of Medical Laboratory Immunology

Academic Office Information

  • 801-213-2809
  • H&I Lab
    417 Wakara way
    Salt Lake City, UT 84108

Email: eszter.lazar-molnar@path.utah.edu

Education History

Type School Degree
Fellowship University of Utah
Immunology
Clinical Fellow
Postdoctoral Fellowship Albert Einstein College of Medicine
Microbiology & Immunology
Postdoctoral Fellow
Research Fellow Cancer Research Institute
Postdoctoral Research Fellow
Doctoral Training Semmelweis University School of Medicine
Genetics, Cell and Immunobiology
Ph.D.
Doctoral Training University of Medicine and Pharmacy of Târgu Mureș
Pharmacy
Pharm.D.

Global Impact

Education History

Type School Degree Country
Doctoral Training Semmelweis University School of Medicine
Genetics, Cell and Immunobiology
Ph.D. Hungary
Doctoral Training University of Medicine and Pharmacy of Târgu Mureș
Pharmacy
Pharm.D. Romania

Selected Publications

Journal Article

  1. Ravkov EV, Charlton CM, Barker AP, Hill H, Peterson LK, Slev P, Tebo A, Voelkerding KV, Wittwer CT, Heikal N, Delgado JC, Lzr-Molnr E, Kumnovics A (2019). Evaluation of Mass Cytometry in the Clinical Laboratory. Cytometry B Clin Cytom, 96(4), 266-274.
  2. Willrich MAV, Lazar-Molnar E, Snyder MR, Delgado JC (2018). Comparison of clinical laboratory assays for measuring serum infliximab and antibodies for infliximab. J Appl Lab Med, 2(6), 893-903.
  3. Lazar-Molnar E, Scandiuzzi L, Basu I, Quinn T, Sylvestre E, Palmieri E, Ramagopal UA, Nathenson SG, Guha C, Almo SC (2017). Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. EBioMedicine, 17, 30-44.
  4. Lazar-Molnar E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, Porcelli SA, Almo SC, Nathenson SG, Jacobs WR Jr (2010). Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A, 107(30), 13402-7.
  5. Lazar-Molnar E, Yan Q, Cao E, Ramagopal U, Nathenson SG, Almo SC (2008). Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci U S A, 105(30), 10483-8.
  6. Lazar-Molnar E, Gacser A, Freeman GJ, Almo SC, Nathenson SG, Nosanchuk JD (2008). The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum. Proc Natl Acad Sci U S A, 105(7), 2658-63.
  7. Profaizer T, Pole A, Monds C, Delgado JC, Lazar-Molnar E (In press). Clinical Utility of Next Generation Sequencing Based HLA typing for Disease Association Testing. Hum Immunol.

Review

  1. Lzr-Molnr E, Delgado JC (2019). Implications of Monoclonal Antibody Therapeutics Use for Clinical Laboratory Testing. [Review]. Clin Chem, 65(3), 393-405.
  2. Lazar-Molnar E, Snyder M (2018). The Role of Human Leukocyte Antigen in Celiac Disease Diagnostics. [Review]. Clin Lab Med, 38(4), 655-668.
  3. Lazar-Molnar E, Delgado JC (2016). Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Laboratory. [Review]. Clin Chem, 62(9), 1186-98.

Patent

  1. Lazar-Molnar E, Almo SC (2014). A Selective High-Affinity Immune Stimulatory Reagent And Uses Thereof, International Patent No. PCT/US2014/15235. U.S. Patent No. WO 2014124217 A1. Washington, D.C.:U.S. Patent and Trademark Office.